U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular LymphomaBusiness Wire • 02/27/24
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in GenmabGlobeNewsWire • 02/23/24
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerBusiness Wire • 02/02/24
Genmab Announces Decision in Arbitration Appeal under License Agreement with JanssenGlobeNewsWire • 01/22/24
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 01/19/24
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 01/09/24
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical CancerBusiness Wire • 01/09/24
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsGlobeNewsWire • 01/03/24
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)PRNewsWire • 12/09/23
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)Business Wire • 12/09/23
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular LymphomaGlobeNewsWire • 11/27/23
Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabGlobeNewsWire • 11/21/23